Compare WTBA & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTBA | DNA |
|---|---|---|
| Founded | 1893 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 488.6M | 458.6M |
| IPO Year | 2002 | 2020 |
| Metric | WTBA | DNA |
|---|---|---|
| Price | $28.67 | $8.56 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $24.00 | $8.50 |
| AVG Volume (30 Days) | 36.3K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.17% | N/A |
| EPS Growth | 35.21 | ★ 46.49 |
| EPS | ★ 1.26 | N/A |
| Revenue | N/A | ★ $170,155,000.00 |
| Revenue This Year | $23.80 | N/A |
| Revenue Next Year | $9.39 | N/A |
| P/E Ratio | $23.18 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $19.03 | $5.37 |
| 52 Week High | $30.33 | $17.58 |
| Indicator | WTBA | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 53.55 | N/A |
| Support Level | $27.54 | N/A |
| Resistance Level | $30.12 | N/A |
| Average True Range (ATR) | 0.48 | 0.00 |
| MACD | -0.04 | 0.00 |
| Stochastic Oscillator | 38.04 | 0.00 |
West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings, and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.